Work

360P ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.10.398

Authors: Z. Piotrowska, M-J. Ahn, Y-K. Pang, S.H. How, K. Sang-We, P.J. Voon, D.L. Cortinovis, J. De Castro Carpeno, M. Tiseo, D. Rodriguez Abreu, S.S. Ramalingam, J. Li, L. Servidio, S. Sadow, R.J. Hartmaier, B.C. Cho

Institutions: Massachusetts General Hospital, Samsung Medical Center, Sungkyunkwan University, University of Malaya, International Islamic University Malaysia, Asan Medical Center, Sarawak General Hospital, Azienda Ospedaliera San Gerardo, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research, University of Parma, Emory University, Winship Cancer Institute, AstraZeneca (United States), Yonsei University, Yonsei Cancer Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: AstraZeneca

OpenAlex ID: W4310753904

FWCI: 0.846

Cites:

Cited by: 8

Related to: 10